VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA

BACKGROUND: We investigated the safety and efficacy of bevacizumab combined with gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas cancer (APCA). DESIGN: Patients with untreated APCA received bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2) over 100 min, and 5...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Martin, L. K., Li, X., Kleiber, B., Ellison, E. C., Bloomston, M., Zalupski, M., Bekaii-Saab, T. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841413/
https://ncbi.nlm.nih.gov/pubmed/22767582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds134
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados